Tesla Recalls Model...
Health Care: Drugs
Onyx Pharmaceuticals Inc. (ONXX: NASDAQ)
$85.54 -3.26 | -3.67%
06/19/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 88.80 |
| 52 Week High | 101.57 |
| 52 Week Low | 63.00 |
| Avg. Daily Vol. (Mil) | 1.14 |
| Beta (3 year) | 1.69 |
| Share Related Items | |
| Mkt Cap (Mil) | 6,459.16 |
| Shares Out (Mil) | 72.74 |
| Float (Mil) | 61.80 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 8.40 |
| Current Ratio | 9.00 |
| LT Debt/ Equity | 0.15 |
| Total Debt / Equity | 0.15 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 14.83 |
| Price/Book | 5.57 |
| Price/Cash Flow | -48.60 |
| Per Share Data | |
| Earnings | -2.50 |
| Sales | 5.99 |
| Book Value | 15.93 |
| Cash Flow | -1.83 |
| Business Summary | |
|---|---|
| Onyx Pharmaceuticals, Inc, is a biopharmaceutical company developing innovative therapies that target the molecular mechanisms that cause cancer. Its products include Nexavar, Stivarga, and Kyprolis. | |
| General Information | |
| 249 East Grand Avenue
South San Francisc, CA 94080 |
|
| www.onyx.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 741 | |
| CEO: Dr. N. Anthony Coles, M. | |
| Short Interest | |
| Current Month (Mil) | 5.56 |
| Previous Month (Mil) | 5.03 |
| Short Interest Ratio (Days) | 4.60 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -9.90 |
| Return on Investments | -12.00 |
| Profitability | |
| Gross Margin | 99.20 |
| EBIT Margin | -59.10 |
| Profit Margin | -37.90 |
Portfolios with ONXX
- Portfolio NameUser Type
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- ContributorStocks Rising On Unusual Vo...
- Contributor4 Drug Stocks Facing FDA Ap...
- ContributorHot Biotech Stocks Traded b...
- ContributorStocks Rising On Unusual Vo...
- Userplayers
- ContributorBreakout Stocks Of The Week...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks Rising On Unusual Vo...
Latest ONXX Headlines from TheStreet
- Onyx Pharmaceuticals Inc. (ONXX): Today's Featured Drugs Laggard 06.18.13 | 05:06 pm
- DVAX, RDY, ONXX, ALXN And VRX, 5 Health Care Stocks Pushing The Sector Lower 06.10.13 | 01:06 pm
- FDA's Flawed Call On Aveo's Tivozanib 06.07.13 | 05:06 pm
- Aveo's Future Depends on Triple-Negative Breast Cancer 06.06.13 | 08:06 am
- Onyx Stock Falls On Unusually High Volume (ONXX) 06.03.13 | 03:06 pm
- ASCO '13: Onyx's Nexavar Delays Growth of Thyroid Cancer 06.02.13 | 07:06 am
- Aveo Chairman: Expect 'Consequences" From Kidney Cancer Drug Debacle 05.29.13 | 11:05 am
- Onyx Pharmaceuticals Inc. Stock Hold Recommendation Reiterated (ONXX) 05.24.13 | 10:05 am
- 5 Stocks Raising The Drugs Industry Higher 05.23.13 | 01:05 pm
- Onyx Pharmaceuticals Inc. (ONXX): Today's Featured Drugs Laggard 05.21.13 | 05:05 pm
Press Releases for ONXX
- Bayer's Stivarga® (regorafenib) Tablets Approved In Japan - PR Newswire 03.25.13 | 05:03 pm
- Bayer's Stivarga® (regorafenib) Tablets Approved By U.S. FDA For Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic GIST - PR Newswire 02.25.13 | 04:02 pm
- Onyx Pharmaceuticals Launches Make Your Mark At The Multiple Myeloma Experience To Champion Progress In Multiple Myeloma Research And Treatment - PR Newswire 12.06.12 | 04:12 pm
- Onyx Pharmaceuticals To Present At Upcoming Investor Conferences - PR Newswire 09.04.12 | 04:09 pm
- Bayer Submits New Drug Application For Regorafenib For The Treatment Of Gastrointestinal Stromal Tumors (GIST) - PR Newswire 08.30.12 | 10:08 am
- Onyx Pharmaceuticals Announces Kyprolis⢠Study Published In The Medical Journal Blood - PR Newswire 07.25.12 | 09:07 am
- Onyx Pharmaceuticals To Report Second Quarter 2012 Financial Results After Market On August 1, 2012 - PR Newswire 07.23.12 | 04:07 pm
- Addition Of Tarceva® (erlotinib) To Nexavar® (sorafenib) Did Not Provide Additional Benefit To Patients With Unresectable Liver Cancer Versus Nexavar Alone In Phase 3 Trial - PR Newswire 07.23.12 | 02:07 am
- Onyx Pharmaceuticals Receives FDA Accelerated Approval Of Kyprolis⢠(carfilzomib) For Injection - PR Newswire 07.20.12 | 12:07 pm
- Onyx Pharmaceuticals Names John E. Osborn Senior Vice President, Global Corporate Affairs - PR Newswire 07.09.12 | 08:07 am
Partner Headlines for ONXX
- Deutsche Bank Reiterates Buy on Onyx Pharmaceuticals on Updated Guidelines - Benzinga 03.11.13 | 01:03 pm
- Four Biotech Stocks On The Clock - Seeking Alpha 02.19.13 | 09:02 am
- Onyx Pharmaceuticals (ONXX) - Bull of the Day - Zacks 12.05.12 | 01:12 am
- Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX) - Benzinga 11.12.12 | 01:11 pm
- Celgene Earnings Beat Views; Guidance Raised A Bit - Investor's Business Daily 10.25.12 | 04:10 pm
- Onyx Enrolls FOCUS Patients - Analyst Blog - Zacks 10.22.12 | 05:10 pm
- CHMP Positive on Novartis' Votubia - Analyst Blog - NASDAQ 09.24.12 | 06:09 pm
- Bulls stay hooked with Onyx uptrend - NASDAQ 09.20.12 | 03:09 pm
- FDA Panel to Review Celgene Drug - Analyst Blog - NASDAQ 09.20.12 | 01:09 pm
- FDA Panel to Review Celgene Drug - Analyst Blog - Zacks 09.20.12 | 10:09 am
